Texas Permanent School Fund Corp Sells 281 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Texas Permanent School Fund Corp cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,846 shares of the biopharmaceutical company’s stock after selling 281 shares during the period. Texas Permanent School Fund Corp’s holdings in Regeneron Pharmaceuticals were worth $21,027,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. Scotia Capital Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $242,000. Creative Planning increased its position in shares of Regeneron Pharmaceuticals by 9.0% in the third quarter. Creative Planning now owns 6,668 shares of the biopharmaceutical company’s stock worth $5,487,000 after purchasing an additional 551 shares during the last quarter. Integrated Advisors Network LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $225,000. Public Sector Pension Investment Board increased its position in shares of Regeneron Pharmaceuticals by 10.7% in the third quarter. Public Sector Pension Investment Board now owns 11,434 shares of the biopharmaceutical company’s stock worth $9,410,000 after purchasing an additional 1,103 shares during the last quarter. Finally, AllSquare Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 89.7% in the third quarter. AllSquare Wealth Management LLC now owns 55 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 26 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,208 shares of company stock worth $62,514,142. 7.48% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on REGN shares. Royal Bank of Canada restated an “outperform” rating and issued a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, June 24th. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday. UBS Group upped their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Finally, TD Cowen upped their target price on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,038.77.

Regeneron Pharmaceuticals Trading Up 0.9 %

REGN traded up $9.15 during trading hours on Thursday, reaching $1,080.27. 444,100 shares of the company’s stock traded hands, compared to its average volume of 472,994. The firm has a 50-day moving average price of $1,008.01 and a 200 day moving average price of $961.64. Regeneron Pharmaceuticals, Inc. has a 52-week low of $714.15 and a 52-week high of $1,091.40. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $119.03 billion, a PE ratio of 31.91, a PEG ratio of 2.17 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.